MoonLake Immunotherapeutics remains a promising clinical-stage biotech, with potentially its first FDA approval in 2026.

Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to persistent weakness in demand for the blockbuster human papillomavirus vaccine ...

Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a treatment for COPD -- to its portfolio. With the stock valued at only 12 ...

Along with its financial results for the second quarter of 2025, Merck revealed a restructuring plan to save $3 billion by the end of 2027.

Merck posted lower Q2 earnings as vaccine sales dropped, but oncology and animal health segments saw strong growth; 2025 guidance slightly raised.

Merck offers a quarterly dividend amount of 81 cents per share. To receive $500 monthly, here's what you do.

Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed second-quarter earnings picture, with adjusted earnings surpassing analyst ...

A change in full-year guidance by management wasn't particularly welcome.

Merck & Co., Inc. (NYSE: MRK) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A close-up of a person’s hand holding a bottle of pharmaceuticals.

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a trial last year, the firm’s cancer drug outperformed the world’s ...

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world.